Testing

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.

By Barbara J. Toman • February 7, 2023

In January 2023, Mayo Clinic Laboratories announced fifty-nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Samantha Rossi • February 2, 2023

This page includes updates posted to the site during the month of January.

By Michael Hutchison • February 2, 2023

Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.

By Barbara J. Toman • January 31, 2023

Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.

By Barbara J. Toman • January 17, 2023

In December 2022, Mayo Clinic Laboratories announced seventy-eight new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Samantha Rossi • January 5, 2023

This page includes updates posted to the site during the month of December.

By Michael Hutchison • January 3, 2023

Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.

By Robin Huiras-Carlson • December 14, 2022

This list includes updates posted to mayocliniclabs.com during the month of November.

By Michael Hutchison • December 2, 2022

In November 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Samantha Rossi • December 1, 2022

Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.

By Barbara J. Toman • November 29, 2022

Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.

By Robin Huiras-Carlson • November 22, 2022

Puanani Hopson, D.O., explains how Mayo Clinic Laboratories’ malabsorption panel can provide timelier diagnosis for children with chronic diarrhea or unexplained weight loss. The novel panel, which bundles four existing tests, requires just one stool sample.

By Barbara J. Toman • November 15, 2022